Oncology

Study investigators also found that dietary modifications were not associated in improving risks of certain chronic diseases and cancers.

This is the first approval of an EB virus-related mRNA therapeutic cancer vaccine and is a landmark achievement in future research on cancer treatment.

Investigators noted that the conditional overall survival also had clinically meaningful improvements compared with sorafenib for advanced renal cell carcinoma.

A clinical pharmacist discusses his work in the mental health space while stressing the importance of advocating for and checking in with one another’s emotional well-being.

Compared with placebo, acalabrutinib plus standard of care chemoimmunotherapy demonstrated better progression-free survival in patients with mantle cell lymphoma.

CAR T-cells specifically targeting FCRL5, when integrated with IL-15, may improve cytotoxicity, thereby enhancing the therapeutic potency of these cells.

In Iraq, asymmetrical warfare tactics relied heavily on unconventional weaponry, requiring military physicians to improvise new medical techniques in order to increase rates of survival.

Pharmacists can raise awareness for lung cancer during and after Lung Cancer Action Week.

The new administration method, which is co-formulated with rHuPH20, is usable in previous approved nivolumab indications for solid tumors in adult patients.

Despite the increased survival rates in all 4 evaluated racial groups, both adult and pediatric non-Hispanic African American patients continued to have worse outcomes.

Scott Soefje discusses new treatment options for prostate cancer and highlights the important role pharmacists can play in coordinating care.

The vice president of pharmacy operations at American Oncology Network says that pharmacists can contribute by educating patients and offering resources for support and treatment adherence.

The screenings should be conducted every other year, beginning at age 40 and continuing through age 74, according to the new recommendation.

With 50 biosimilar products approved by the FDA, questions arise regarding biosimilar lifecycles and sustainability of the industry.

The investigators note that additional research is needed to confirm positive overall survival trends in this patient population.

Tisotumab vedotin-tftv is the first antibody-drug conjugate to demonstrate positive overall survival data in patients with previously treated recurrent or metastatic cancer.

According to the speaker, the complexity of immune-related adverse events resulting from immune checkpoint inhibitors requires a lot of collaborative discussion between patients and providers.

Trastuzumab is indicated for adjuvant breast cancer, metastatic breast cancer, and gastric cancer.

Tovorafenib is the first systemic therapy to be approved for the treatment of pediatric patients who have low-grade glioma with BRAF rearrangements or fusions.

Dostarlimab plus chemotherapy is the only immuno-oncology-based therapy that showed statistically significant and clinically meaningful survival benefit in the overall patient population.

This year’s event from June 20 to 21, 2024, in Austin, Texas, will offer 4.25 BCOP CE hours.

Advances, challenges, and promising innovations emerge.

A 76% lower risk was displayed with adjuvant alectinib compared to chemotherapy treatment for non–small cell lung cancer.

Successful integration demands overcoming various hurdles.

This approval makes lutetium Lu177 the first therapy to be approved for the treatment of gastroenteropancreatic neuroendocrine tumors in pediatric patients.

The approval was based on the QUILT-3.032 study, which included 77 adults with carcinoma in situ with or without papillary tumors after a transurethral resection.

PAPs in this model can significantly reduce OOP costs regardless of the pharmacy setting.

The trial will compared the efficacy, safety, pharmacokinetics, and immunogenicity between SB27 and pembrolizumab for metastatic non-squamous non-small cell lung cancer.